Back to top
more

Homology Medicines, Inc. (FIXX)

(Delayed Data from NSDQ)

$22.32 USD

22.32
182,759

+0.63 (2.90%)

Updated May 3, 2019 04:00 PM ET

After-Market: $22.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Homology Medicines (FIXX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Homology Medicines (FIXX) and Ono Pharmaceutical Co. (OPHLF) have performed compared to their sector so far this year.

Will Homology Medicines (FIXX) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Homology Medicines (FIXX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Homology Medicines (FIXX) stock based on the movements in the options market lately.

    Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of 6.90% and 249.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Homology Medicines (FIXX) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of 96.92% and 3681.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will Homology Medicines (FIXX) Report Negative Q1 Earnings? What You Should Know

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Homology Medicines (FIXX) Surges 5.9%: Is This an Indication of Further Gains?

    by Zacks Equity Research

    Homology Medicines (FIXX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Homology Medicines (FIXX) Q4 Earnings Expected to Decline

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Bausch (BHC) Begins Second Phase III Study on NOV03 for DED

    by Zacks Equity Research

    Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.

    Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of 3.70% and 20.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Homology Medicines (FIXX) Q2 Earnings Expected to Decline

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Homology Medicines (FIXX) Looks Good: Stock Adds 8% in Session

    by Zacks Equity Research

    Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

    Biomarin to File Regulatory Applications for Vosoritide in Q3

    by Zacks Equity Research

    BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.

    Is Homology Medicines (FIXX) Stock a Solid Choice Right Now?

    by Zacks Equity Research

    Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

    Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    BioMarin to Begin Early-Stage Study on Gene Therapy for PKU

    by Zacks Equity Research

    BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

    Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of -15.52% and 17.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Homology Medicines (FIXX) Q3 Earnings Expected to Decline

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Homology Medicines (FIXX) delivered earnings and revenue surprises of -16.36% and -73.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?